繼表皮生長因子受體(EGFR)基因突變和間變性淋巴瘤激酶(ALK)基因融合之后,Met基因激活突變和擴增被認為是非小細胞肺癌(NSCLC)下一個重要的驅(qū)動基因,它與腫瘤的增殖、侵襲、轉(zhuǎn)移及血管生成密切相關,已成為靶向治療領域研究的一大亮點。主要靶向治療藥物可分為抗HGF單克隆抗體、抗c-Met單克隆抗體和小分子抑制劑3類,并多已進入臨床試驗階段。對作用于Met靶點的非小細胞肺癌治療藥物的研究進展進行綜述。

Following the gene mutation of epidermal growth factor receptor (EGFR) and gene fusion of anaplastic lymphoma kinase (ALK), Met activating mutations and gene amplification are considered to be the next important driver gene of non-small-cell lung cancer (NSCLC), which is associated with tumor proliferation, invasion, metastasis, and angiogenesis. And this has become a major aspect of tumor targeted therapy research. The main targeted therapy drugs can be divided into anti-HGF monoclonal antibody, anti-c-Met monoclonal antibodies and small molecule inhibitors, and more of them have entered clinical trials. This review focuses on the latest research on c-Met and its targeted therapy drugs.